German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
EMA Committee for Medicinal Products for Human Use rcommended use of Modernaﾒs BA.1 bivalent COVID-19 booster in children n the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
Oxford Ebola vaccine manufactured and shipped in record time by Serum Institute of India
On Dec. 15, 2022, the University of Oxford Oxfordﾒs Ebola vaccine candidate has been shipped to Uganda, just…
Ebola vaccine regimens safe, immunogenic in adults and children
On Dec. 14, 2022, the National Institutes of Health announced that two randomized, placebo-controlled trials evaluating three Ebola…
High path Avian influenza confirmed in Clackamas County backyard flock
On Dec. 12, 2022, the Oregon Department of Agriculture and the U.S. Department of Agriculture’s Animal Plant Health…
Swiss and French health authorities expanded recommendations for use of Nuvaxovid COVID-19 vaccine as booster
On Dec. 11, 2022, Novavax announced that the Switzerland�s Federal Office of Public Health and France�s Haute Autorit�…
Biotechnology | COVID-19 | FDA | Influenza | Life Science News | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
COVID-19 vaccine from Washington University in St. Louis approved for use as booster in India
On Dec. 9, 2022, Washington University in St. Louis announced that it’s nasal COVID-19 vaccine technology had been…
Ebola trial candidate vaccines arrived in Uganda in record 79 days after outbreak declared
On Dec. 9, 2022, the WHO announced that the first doses of one of the three candidate vaccines…
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
Biotechnology | COVID-19 | FDA | Life Science News | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
Biotechnology | COVID-19 | Life Science News | Therapeutics | Vaccine | WHO
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
Scientists revealed encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach
On Dec. 2, 2022, in a multi-center collaboration led by Scripps Research, scientists announced they have achieved promising…
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
WHO to identify pathogens that could cause future outbreaks and pandemics
On Nov. 21, 2022, the WHO is launching a global scientific process to update the list of priority…
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint of superiority against omicron variants
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
University of Missouri study found Monkeypox mutations caused virus to spread rapidly, evade drugs and vaccines
On Nov. 9, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
Pfizer announced positive top-line data of phase 3 global trial for bivalent RSV vaccine candidate
On Nov. 1, 2022, Pfizer announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal…
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
Biotechnology | HIV | Life Science News | NIH | Vaccine
Three-dose hepatitis B vaccine regimen protected people with HIV
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
90-Day analysis showed Moderna’s Omicron BA.1-targeting bivalent vaccine, mRNA-1273.214, demonstrated superior antibody response as fourth booster Compared to Spikevax Prototype Booster
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
Pfizer and BioNTech received positive CHMP ppinion for COMIRNATYﾮ in children 6 months to less than 5 lears in EU
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products…